Form 4: Director Schabacker Receives Enveric Stock Grant

Enveric Biosciences Director Marcus Schabacker was granted 7,633 shares of restricted common stock, adjusted for recent reverse stock splits.

Summary

• Marcus Schabacker, a Director of Enveric Biosciences, Inc. (ENVB), acquired 7,633 shares of common stock on December 23, 2025.
• The shares were granted as restricted stock under the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended, with an acquisition price of $0 per share.
• Following this transaction, Marcus Schabacker directly beneficially owns 7,900 shares of common stock.
• The reported share numbers have been adjusted to reflect two reverse stock splits: a 1-for-15 split effective January 29, 2025, and a 1-for-12 split effective October 28, 2025.

Sentiment

Score: 6

Explanation: The filing reports a restricted stock grant to a director, which is a positive for aligning management incentives. However, the disclosure of two significant reverse stock splits within the year, while factual, reflects negatively on the company's past stock performance and market perception, balancing the overall sentiment.

Positives

• Grant of restricted stock to a director aligns management interests with long-term shareholder value.
• The grant is part of an established long-term incentive plan, indicating structured compensation practices.

Negatives

• The company underwent two significant reverse stock splits (1-for-15 on January 29, 2025, and 1-for-12 on October 28, 2025) within the year, which often indicates challenges with share price or maintaining listing compliance.

Future Outlook

The granted restricted shares are subject to vesting in accordance with the terms and conditions of the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan and the reporting person's restricted stock award agreement.

Industry Context

The grant of restricted stock to a director is a common practice in the biotechnology and pharmaceutical industry to incentivize long-term commitment and align leadership interests with company performance. However, the occurrence of two reverse stock splits within a year suggests the company may be navigating challenges common to smaller-cap biotech firms, such as maintaining stock exchange listing requirements or addressing low share price.

Comparison to Industry Standards

• Restricted stock grants are a standard component of executive and director compensation packages across the biotech sector, comparable to practices at companies like Moderna or BioNTech, though the scale of grants varies significantly with company size and stage.
• Reverse stock splits, while not unique, are often a measure taken by companies, particularly in the volatile biotech sector, to increase share price and meet minimum bid price requirements for major exchanges, similar to actions seen historically by companies like Aeterna Zentaris Inc. or Sorrento Therapeutics, Inc. when facing delisting risks.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of restricted stock to a director aims to align management incentives with shareholder interests, potentially fostering long-term value creation. However, the prior reverse stock splits may have diluted existing shareholder value or indicated underlying stock performance issues.

Next Steps

• Vesting of the 7,633 restricted shares according to the terms of the 2020 Long-Term Incentive Plan and the award agreement.

Key Dates

Keywords

Enveric Biosciences, ENVB, Marcus Schabacker, Restricted Stock, Stock Grant, Director Compensation, Reverse Stock Split, Insider Transaction, Form 4